26 results
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
of Allowance demonstrates our commitment to protecting Allocetra’s™ commercial opportunities in key geographies around the world. It also highlights
FWP
ENLV
Enlivex Therapeutics Ltd
9 Feb 21
Free writing prospectus
5:21pm
., LLC under which the underwriter has agreed to purchase on a firm commitment basis 500,000 ordinary shares, par value NIS 0.40 per share, of the Company
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
19 Nov 14
Bio Blast Pharma Receives Orphan Drug Designation
12:00am
are very favorable conditions to continue to pursue our clinical plans and reflects our commitment to those patients suffering from rare diseases
FWP
ENLV
Enlivex Therapeutics Ltd
10 Feb 21
Free writing prospectus
6:08am
agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 2,296,107 ordinary shares, par value NIS 0.40
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
27 Mar 19
Securities Purchase Agreement
8:32am
allocated (provided that there is no commitment, including a conditioned commitment, by the Company to allocate the shares).
The General Meeting
F-1/A
EX-3.2
y0ox6w4c
8 Jul 14
Registration statement (foreign) (amended)
12:00am
6-K
EX-99.1
45bsum0j 1kpk
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
6-K
EX-99.2
kn65xa 80tw
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
6-K
EX-99.1
jg8l5n1gw5
19 Nov 18
Agreement and Plan of Merger
4:34pm
6-K
EX-99.1
53438
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
6-K
EX-99.1
dw75qz
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
424B5
bobs3gua4 89bfw2qbd
26 Feb 20
Prospectus supplement for primary offering
8:23am
6-K
EX-10.1
fgnsj bjfa8
22 Oct 20
Report of Foreign Private Issuer
8:47am
424B5
xd5fcofn7qhw2feiuhs8
3 Mar 20
Prospectus supplement for primary offering
5:13pm
6-K
EX-99.2
r3ueqommyw8 cbm
6 Dec 18
Amended Notice of Annual and Extraordinary General Meeting of the Shareholders
4:43pm
F-1/A
ojnapknh6skmojyr h7b
8 Jul 14
Registration statement (foreign) (amended)
12:00am